Sequential RAS mutation testing in cfDNA in RAS wild type (wt) metastatic colorectal cancer (mCRC) patients (pt) treated with panitumumab (P) and chemotherapy (CT) in first-line (1L): PERSEIDA study

Valladares‐Ayerbes, Manuel; García‐Alfonso, Pilar; Luengo, Jorge Muñoz; Cáceres, Paola Pimentel; Viéitez, J.M.; Cruz-Hernández, Juan J.; Llanos, Marta; Girón, Carlos García; Cirera, Luis; Vila, A. Lloansi

doi:10.1093/annonc/mdz246.009

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PERSEIDA was an observational prospective study in patients with RAS wt mCRC, most of whom were on panitumumab. In this study, liquid biopsies were collected at 20 ± 2 weeks and at disease progression [ 65 , 68 ]. MAF cut-offs of ≥ 1%, ≥ 0.1%, and ≥ 0.02% were considered, whose negative correlations with tumor tissue biopsy were 97.5%, 95%, and 87.4%, respectively.…”

Section: Resultsmentioning

confidence: 99%

Controversies in the treatment of RAS wild-type metastatic colorectal cancer

et al. 2020

View full text Add to dashboard Cite

Objective To provide guidance for the management of RAS wild-type (wt) metastatic colorectal cancer (mCRC) in daily practice. Methods Nominal group and Delphi techniques were used. A steering committee of seven experts analyzed the current management of RAS wt mCRC, through which they identified controversies, critically analyzed the available evidence, and formulated several guiding statements for clinicians. Subsequently, a group of 30 experts (the expert panel) was selected to test agreement with the statements, through two Delphi rounds. The following response categories were established in both rounds: 1 = totally agree, 2 = basically agree, 3 = basically disagree, 4 = totally disagree. Agreement was defined if ≥ 75% of answers were in categories 1 and 2 (consensus with the agreement) or 3 and 4 (consensus with the disagreement). Results Overall, 71 statements were proposed, which incorporated the following areas: (1) overarching principles; (2) tumor location; (3) triplets; (4) maintenance; (5) second-line and beyond treatments; (6) Rechallenge and liquid biopsy. After the two Delphi rounds, only six statements maintained a lack of clear consensus. Conclusions This document aims to describe the expert’s attitude when dealing with several common clinical questions regarding patients with RAS wt mCRC.

show abstract

Section: Resultsmentioning

confidence: 99%